Dr. Axel Adams grew up in rural Wisconsin and attended the University of Wisconsin where he studied potato genetics and molecular biology. He then attended the University of California - San Francisco for medical school while doing a masters at the University of California-Berkeley School of Public Health with a focus in clinical toxicology. During this time, his research was primarily regarding new psychoactive substance surveillance and biomonitoring and mass spectrometry method development. He completed emergency medicine residency at the University of Washington and completed fellowship at the Toxikon Consortium in Chicago. He is currently involved in the development of a regional toxicosurveillance laboratory in Chicago. His interests include drug discovery from natural products, mass spectrometry, occupational toxicology, bioremediation, botany, and lichenology.

Dr. Aldy initially joined the Toxicology Investigators Consortium with the American College of Medical Toxicology as the first ToxIC intern, where she led a vaping initiative around the country. In her new position with ToxIC, Dr. Aldy is responsible for the day to day management of the ToxIC program, staff and site coordination, helping with research projects and publications, and acquiring support for ToxIC through grants and related activities.

Dr. Aldy earned her medical degree at the University of North Texas Health Science Center in Fort Worth, Texas. During her medical school training, she concurrently applied and enrolled in an MBA program with concentration in Health Management at the University of North Texas which she attained shortly after starting residency. She completed an emergency medicine residency at Western Michigan University in Kalamazoo, Michigan. She attended her Medical Toxicology Fellowship at University of Texas at Southwestern Medical Center in Dallas, Texas. 

Dr. Aldy has an academic and clinical affiliation within the departments of Emergency Medicine and Medical Toxicology at the Baylor University Medical Center in Dallas, Texas.

Dr. Culbreth joined the Toxicology Investigators Consortium/ACMT in May 2022. She received her PhD and MPH in epidemiology and biostatistics from Georgia State University. Her dissertation focused on the development of novel statistical methods to measure current and amount of substance use in a hybrid structural equation mixture model framework. She was an Assistant Professor in the College of Nursing and Health Professions at Georgia State University from 2019-2022, where she taught undergraduate and graduate-level research methods, healthcare leadership, and advanced statistical topics for pre-doctoral students. As ToxIC's Research Director, she leads new grant development and scientific dissemination through manuscripts and presentations, and enjoys working closely with clinical colleagues to advance medical toxicology research and practice.

Nabarun Dasgupta, PhD, MPH, is a street drug scientist, whose passion is telling true stories about health with numbers. Centered in pharmaco-epidemiology, his work amplifies community and patient voices in public health. Since 2002 he has done pioneering work in overdose prevention and addiction treatment. He is a recipient of the 2025 MacArthur ""genius"" Fellowship. In 2023 he was placed on the TIME100 Next list of rising global leaders.

As an applied epidemiologist, Dasgupta has served as an advisor to the US Food and Drug Administration (FDA) and World Health Organization (WHO). Operating with an appreciation for the social determinants and of health, the UNC Street Drug Analysis Lab has used GCMS to test nearly 20,000 drug samples provided voluntarily by community organizations and medical providers from around the country. 

Dasgupta co-founded two pioneering non-profit organizations: Project Lazarus and Remedy Alliance For The People, a groundbreaking national non-profit bulk distributor of free and low-cost naloxone to harm reduction programs.

Previously he was the Chief Science Officer of Epidemico, a health informatics startup he co-founded using technology developed at Harvard Medical School. He is also an associate editor at the American Journal of Public Health. Dasgupta earned degrees from Princeton, Yale, and UNC.

Follow the free Opioid Data Lab newsletter at OpioidData.org.

Leslie R. Dye, MD is triple board certified in emergency medicine, medical toxicology, and addiction medicine. She has worked in the fields of medical toxicology and addiction medicine for 30 years. In addition to her clinical expertise, she has academic and business content expertise from experiences as an editor-in-chief (EIC) of a peer-reviewed medical journal (Journal of Medical Toxicology) and EIC of physician and pharmacist content production for a leading international medical digital content provider. Her deep subject matter expertise is demonstrated in her role as senior editor of the textbook, Case Studies in Medical Toxicology, author of 18 peer reviewed publications and 16 textbook chapters, 66 national and 11 international presentations, 10 various commentaries, interviews, and podcasts. Her leadership skills have been proven in both corporate and academic environments, as professor at a medical school, long-term board member and past president of the American College of Medical Toxicology, Chair of the Addiction Medicine Committee, former co-chair, and co-moderator of the AACT Acute and Intensive Care Symposium, and as the manager of as many as 30 team members at an international corporation. She received a funded grant that enabled her to start the first poison control center in mainland China and trained 6 Chinese physicians in the field of medical toxicology over 3 years in the US. Dr. Dye is experienced in and continues to provide medical care in remote polar regions with no access to advanced medical facilities.

David H. Epstein, Ph.D., is an Senior Investigator at the NIDA Intramural Research Program in Baltimore. He earned his doctorate in 1998 in the Biopsychology & Behavioral Neuroscience program at Rutgers University, studying both behavioral pharmacology in rats and neuropsychological assessment in humans, and teaching courses on drug use and addiction. Since then, he has overseen clinical trials and natural-history studies in people who use opioids, cocaine, and kratom. His research interests include multilevel modeling of repeated-measures data, using ambulatory technology for assessment and treatment, and integrating social-structural with person-level explanations of behavior.

Yarelix Estrada, MSPH, is a first-generation Central American, harm reduction researcher, advocate, and psychedelic community organizer. Yarelix works as a technical assistance advisor and trainer for Drug Checking for the People, a project of Remedy Alliance for the People, standing up drug checking programs across the Americas that are centered in drug user rights and autonomy. Yarelix previously worked as a City Research Scientist with the New York City Department of Health and Mental Hygiene conducting community-based substance use harm reduction outreach and research where she was largely focused on implementation of the first higher-technology drug checking project in NYC with local syringe service programs and an overdose prevention center. Yarelix is passionate about supporting people throughout the full continuum of drug use, from use for pleasure and healing to overdose prevention. She is also the director of the New York City Psychedelic Society, is on the Board of Directors for the Source Research Foundation and is an organizer with the Alliance for Collaborative Drug Checking and the National Survivors Union. She received her Master of Science in Public Health in Health Policy at the Johns Hopkins Bloomberg School of Public Health.

Alyssa joined the Toxicology Investigators Consortium/ACMT in November 2023. Alyssa earned her PhD in epidemiology from the University of Florida and her MSPH from the University of Miami. While at the University of Florida, Alyssa was trained in psychiatric epidemiology as a National Institute on Drug Abuse T32 Pre-Doctoral Fellow in the UF Substance Abuse Training Center in Public Health. In 2023, Alyssa was awarded the College on Problems of Drug Dependence’s Female Opioid-addiction Research and Clinical Experts (FORCE) Junior Investigator Award for her research addressing opioid use and non-medical use among middle and older adults.

James R. Gill MD is the Chief Medical Examiner of Connecticut, past Chair of the Forensic Pathology Committee of the College of American Pathologists (CAP), and a past President of the National Association of Medical Examiners (NAME).  He has faculty medical appointments at Yale, University of Connecticut, and Quinnipiac University.  He did his pathology training at Yale and Memorial Sloan-Kettering Cancer Center and his forensic pathology fellowship at the New York City Office of Chief Medical Examiner.  Prior to Connecticut, he was the Deputy Chief Medical Examiner for Bronx County.  He has testified over 450 times in criminal and civil matters in State and Federal courts and has published over 100 scientific articles and book chapters, and two books on a variety of forensic pathology topics.  He has particular interests in public health including drug intoxication deaths, infectious disease, fatal complications of therapy, and proper death certification.

Dr. Rob Hendrickson graduated from the State University of New York, Downstate College of Medicine, and completed training in Emergency Medicine and Medical Toxicology at the Medical College of Pennsylvania. He is a Professor of Emergency Medicine at Oregon Health and Sciences University where he is Chief of the Section of Medical Toxicology, Program Director for the fellowship in medical toxicology, and the Medical Director of the Oregon Poison Center.

Dr. Alex J. Krotulski serves as a Director at the Center for Forensic Science Research and Education (CFSRE) working in the areas of forensic toxicology and forensic chemistry and is the Program Manager for NPS Discovery, the CFSRE’s drug early warning system and flagship program for the identification and characterization of new and emerging synthetic drugs. Dr. Krotulski is a chemist by training and practices as a forensic toxicologist. Dr. Krotulski holds faculty appointment and serves as the Program Director for the Thomas Jefferson University Master of Science in Forensic Toxicology (MSFT) program and is an Senior Associate Editor for the Journal of Analytical Toxicology.

Dr. Michael Lynch is an associate professor of Emergency Medicine, Toxicology, and Addiction Medicine at the University of Pittsburgh where he works clinically in several UPMC hospitals. He is currently Senior Medical Director for Quality and Substance Use Disorder Services at UPMC Health Plan. He previously served as the first Medical Director of the PA Department of Drug and Alcohol Programs and was Medical Director of the Pittsburgh Poison Center for 10 years. He is the founder and director of the UPMC Medical Toxicology Telemedicine Bridge Clinic.

Lewis S. Nelson, MD, MBA, is Dean and Chief of Health Affairs at Florida Atlantic University’s Charles E. Schmidt College of Medicine. A nationally recognized leader in emergency medicine, medical toxicology, and addiction medicine, Dr. Nelson brings over three decades of experience in clinical care, education, and academic leadership. Prior to joining FAU in 2025, he served as Professor and founding Chair of Emergency Medicine at Rutgers New Jersey Medical School, where he also led the Division of Medical Toxicology and Addiction Medicine and served as Chief of Service for the Emergency Department at University Hospital of Newark.

Dr. Nelson has held numerous national leadership positions, including President of the American College of Medical Toxicology and the Association of Academic Chairs in Emergency Medicine, and board roles with the American Board of Emergency Medicine, the Accreditation Council for Continuing Medical Education, and the Society for Academic Emergency Medicine. A prolific scholar, he has authored more than 300 peer-reviewed publications and serves as lead editor of Goldfrank’s Toxicologic Emergencies, the definitive reference in medical toxicology. His work focuses on emergency medicine, toxicology, addiction medicine, and health policy, with an emphasis on improving patient safety and advancing evidence-based care.

Simon Ostrowski graduated from Boston University for his undergraduate degree and University of Massachusetts Medical School. He went on to complete his emergency medicine residency and medical toxicology fellowship at University of Pittsburgh Medical Center. Following fellowship, Dr. Ostrowski accepted a faculty position in emergency medicine and medical toxicology at UMass Chan Medical School. His academic interests include alcohol withdrawal, addiction medicine, and the intersection of toxicology and public health particularly the emergence of novel psychoactive substances.

Dr. Stephanie Weiss is the Staff Research Physician serving the National Institute on Drug Abuse’s Intramural Research Program. After earning a Ph.D. in pharmaceutical chemistry, Dr. Weiss received her medical degree in 2011. She is board certified in addiction medicine and medical toxicology and participated in the Boston University Research in Addiction Medicine Scholars Program prior to joining NIDA. Dr. Weiss is responsible for providing optimal, safe, and ethical care to study participants and clinical support toward the NIDA IRP mission of conducting inpatient and outpatient proof-of-concept human laboratory therapeutic and imaging studies for addictive disorders. Her research interests include GLP-1RAs, medication misuse, and improving interpretation of urine drug testing.

Dr. Rachel Wightman is an Associate Professor of Emergency Medicine and Epidemiology at Alpert Medical School of Brown University. Trained in Emergency Medicine and Medical Toxicology at Bellevue Hospital, New York University, New York City Poison Control Center Dr. Wightman currently serves as the Director of Toxicology and Addiction Medicine for Brown Emergency Medicine and is a Consultant Medical Director at the Rhode Island Department of Health. She is a NIH-funded Principal Investigator focused on cannabis and opioid use.